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We describe the case of a patient with an empyema, how it forms and what the evidence behind the
treatment options are with speciﬁc reference to intrapleural thrombolytic therapy.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Case
A 54-year-old lady presented to the acute medical take with
progressive dyspnoea over 3 weeks, purulent bronchitis and fevers.
She was a non-smoker with no signiﬁcant medical history.
Clinical examination was consistent with a right sided pleural
effusion which was conﬁrmed on PA and lateral chest radiograph
(Figs. 1 and 2). C-reactive protein (CRP) was 352 mg/L, white cell
count 23109 L with a neutrophilia. Under ultrasound guidance,
a chest drain was inserted and ﬂuid analysis revealed a ﬂuid pH of
7.16, Lactate Dehydrogenase (LDH) of 679 U/L (plasma LDH 304 U/
L), ﬂuid protein of 52 g/L (plasma protein 82) and ﬂuid glucose of
2.3 mmol/L (plasma glucose 6.2 mmol/L). Gram stain was negative
and no organisms were seen.
Two litres of straw coloured ﬂuid drained promptly but, despite
regular ﬂushing with 0.9% saline to maintain drain patency, no
further drainage occurred. The patient continued to exhibit an
inﬂammatory response despite being on 1.2 g of co-amoxiclav and
400 mg of metronidazole intravenously, thrice daily. Repeat
imaging with thoracic ultrasound showed residual pleural collec-
tions with marked septations present. A therapeutic intervention
was performed culminating in further drainage and considerable
clinical improvement. A CT scan of the chest was performed
(Figs. 3e5) and the patient discharged home with early follow-up
(Fig. 6).b).
-NC-ND license.2. Question
What diagnosis is suggested by the pleural ﬂuid analysis?
2.1. Short answer
The analysis is in keeping with an exudative, complicated par-
apneumonic effusion.
2.2. Long answer
Classically, a pleural ﬂuid protein >30 g/l suggests an exudative
cause and <30 g/l a transudative cause. However, it has been
known since 1976 that the reliability of absolute values is poor.1
Hence, the application of Light’s criteria is recommended in the
interpretation of pleural ﬂuid results.2
Pleural ﬂuid is an exudate if one ormore of the following criteria
are met:
1. Pleural ﬂuid protein divided by serum protein is >0.5.
2. Pleural ﬂuid lactate dehydrogenase (LDH) divided by serum
LDH is >0.6.
3. Pleural ﬂuid LDH >2/3 the upper limits of laboratory normal
value for serum LDH.
Light’s criteria are nearly 100 percent sensitive at identifying
exudates, but approximately 20 percent of patients with pleural
effusion caused by heart failure may fulﬁl the criteria for an
exudative effusion after receiving diuretics.3
An empyema is deﬁned as pus in the pleural cavity. In this case
the ﬂuid was straw coloured but the clinical suspicion of pleural
space infection was high. Therefore pH analysis was undertaken.
Fig. 1. CT scan showing a pleural collection of ﬂuid and gas with pleural enhancement
in keeping with presumed infection in the pleural space (empyema).
Fig. 3. CT scan showing a pleural collection of ﬂuid and gas with pleural enhancement
in keeping with presumed infection in the pleural space (empyema).
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to an increase in lactic acid and carbon dioxide production.4
Increased consumption of glucose occurs also such that the
pleural ﬂuid glucose concentration is low.5 Pleural ﬂuid acidosis can
also be associated with malignancy and connective tissue disease
and should therefore be interpreted with the contemporary clinical
picture.Fig. 2. CT scan showing a pleural collection of ﬂuid and gas with pleural enhancement
in keeping with presumed infection in the pleural space (empyema).More importantly, a meta-analysis of studies examining pleural
pH and the need for chest tube drainage or surgery in patients with
parapneumonic effusions found that a pH< 7.2 was the most
speciﬁc discriminator of complicated pleural infection and of the
need for immediate chest drainage.6 The current British Society
Guidelines7 support this and indicate that if pHmeasurement is not
possible, a pleural ﬂuid glucose level <3.4 mmol/l may be used asFig. 4. Follow up ﬁlm after 2 months showing only minor residual right basal pleural
thickening.
Fig. 5. Right sided pleural effusion.
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with the caveat that in certain other conditions like rheumatoid
arthritis, the glucose level may be low too.
3. Question
What is the patho-physiology of this type of effusion?
3.1. Short answer
A progressive process occurs as a simple exudate transitions
through a ﬁbrino-purulent stage culminating in an organising stage
with scar tissue formation.Fig. 6. Right sided pleural effusion.3.2. Long answer
The normal volume of pleural ﬂuid in humans is less than 1 ml
and it forms a thin ﬁlm between parietal and visceral pleura. In the
early inﬂammatory phase, pro-inﬂammatory cytokines cause
increased vascular permeability leading to ﬂuid shift into the
pleural space. This ﬂuid is free ﬂowing and has no bacteriawithin it.
With ongoing damage to the endothelium, bacterial invasion can
occur. This promotes further neutrophil migration and progression
of the immune reaction. Moreover, there is activation of the coag-
ulation cascade and depressed ﬁbrinolytic activity, which leads to
the formation of septations as a result of ﬁbrin deposition.8 A
ﬁbrino-purulent collection follows and is often associated with
a paucity of organisms e as few as 25e30% of empyemas are
actually culture positive.7 The organising stage follows as ﬁbro-
blasts create a solid ﬁbrous pleural peel replacing the soft ﬁbrin.
This can prevent the re-expansion of the lung and create a persis-
tent area of pleural thickening.9
4. Question
What was our therapeutic intervention?
4.1. Short answer
Intrapleural ﬁbrinolytic drugs (streptokinase 250 000 IU twice
daily for 3 days) were given.
4.2. Long answer
In the UK up to 20% of empyema patients come to surgery due to
failed catheter drainage and, overall, 20% of patients with empyema
die.10 Intravenous antibiotics and chest tube drainage are the ﬁrst
line treatments. However, as outlined above, infected ﬂuid can
become septated and hence resist drainage. A meta-analysis from
the Cochrane library11 evaluated four trials12e15 and concluded that
ﬁbrinolytics reduce hospital stay, shorten the period of fever,
produce radiological improvement, and reduce the incidence of
treatment failure (deﬁned as death). However MIST 1, a large
randomised trial of intrapleural streptokinase, failed to show any
beneﬁt in terms of mortality, rates of surgery, radiographic
outcomes, or length of the hospital stay.16 However, all infected
effusions were included in this study from many centres with
varying experience in their management and it is argued that
streptokinase would not work in the effusions in the late organised
stage with hard peels.17 The patients were much older and had
manymore co-morbidities than in the previous trials. The effusions
were also only treated with smaller chest tubes without image
guidance. Our centre has considerable experience managing
complicated parapenumonic effusions utilising image-guided
drainage and intrapleural streptokinase. Streptokinase is adhesio-
lytic and complexes of streptokinase with human plasminogen can
hydrolytically activate other unbound plasminogen to produce
plasmin which breaks ﬁbrin down. However, it is not bactericidal
and does not reduce viscosity of pus which has a high DNA content
from degranulated cells. It is plausible that a combination of agents
that reduce pus viscosity (e.g., DNase) and those that break down
loculations may be necessary to enhance pus drainage. Rahman
et al.18 found that intrapleural tissue plasminogen activator and
DNase therapy improved ﬂuid drainage in patients with pleural
infection and reduced the frequency of surgical referral and the
duration of the hospital stay. This was a study of 201 patients with
pleural infection who received double placebo, intrapleural tissue
plasminogen activator (t-PA) and DNase, t-PA and placebo, or
DNase and placebo for 3 days. The primary outcomewas the change
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surgery, duration of hospital stay, and adverse events.
Our patient had very effective drainage with marked clinical
improvement.5. Question
What was does the CT scan show?5.1. Short answer
There is a pleural collection of ﬂuid and gas with pleural
enhancement in keeping with presumed infection in the pleural
space (empyema).5.2. Long answer
There is a pleural collection of ﬂuid in the lower right thorax
(low attenuation indicates ﬂuid). There is pleural enhancement and
haziness of the extra-pleural fat indicating inﬂammation. There are
several bubbles of gas within the ﬂuid that have not risen to the top
as expected with gravity, indicating loculations within the ﬂuid.
This appearance is in keeping with presumed infection in the
pleural space (empyema).
The right sided percutaneous drain is present within the
collection, but the tip was located anteriorly with the ﬂuid
predominantly postero-lateral. Slight reduction in volume of right
lung is in keeping with secondary atelectasis of the lung adjacent to
the pleural collection.
The drain was removed and the patient sent home to ﬁnish a 6
week course of antibiotics. No organisms were grown from the
pleural ﬂuid and she has made a complete clinical and radiological
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